EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Zejula (niraparib tosilate monohydrate) for ovarian, fallopian tube, and peritoneal neoplasms, under GlaxoSmithKline Trading Services Limited…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Neoplasms
• Ovarian Neoplasms
• Peritoneal Neoplasms

Drugs mentioned

• Zejula (Niraparib)

Snippet

Status: Authorised. Therapeutic area: Fallopian Tube Neoplasms;Peritoneal Neoplasms;Ovarian Neoplasms. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 04/06/2026. Orphan medicine